CORDIS · 648364 · H2020
resistance evolution Bacterial evolution of hypersensitivity and resistance against antimicrobial peptides
Coordinator: HUN-REN SZEGEDI BIOLOGIAI KUTATOKOZPONT (HU)
Evolution of resistance towards a single drug simultaneously increases (cross-resistance) or decreases (collateral sensitivity) fitness to multiple other antimicrobial agents. The molecular mechanisms driving cross-resistance are relatively well described, but it remains largely unclear how frequently does genetic adaptation to a single drug increase the sensitivity to others and what the underlying molecular mechanisms of collateral sensitivity are. This proposal focuses on studying the bacterial evolution of resistance and collateral sensitivity against antimicrobial peptides (AMPs). Beyond…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €1.8M awarded to the consortium. The project runs over approximately 6.5 years from 2015-10-01 to 2022-03-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from HU
see all →- HCEMM — Establishing the Hungarian Center of Excellence for Molecular Medicine in partnership with EMBL739593 · H2020 · €15.0M
- EPIC — Centre of Excellence in Production Informatics and Control739592 · H2020 · €10.9M
- DYNASNET — Dynamics and Structure of Networks810115 · H2020 · €9.3M
- DALIA — Danube Region Water Lighthouse Action101094070 · HORIZON · €8.5M
- DETERMINISTIC6G — DETERMINISTIC E2E COMMUNICATION WITH 6G101096504 · HORIZON · €5.5M
- MOMENTUM PPDF — Momentum Premium Postdoctoral fellowship101179854 · HORIZON · €5.0M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the ERC-COG funding scheme.
- What is the EU contribution?
- The European Commission contributes €1.8M toward a total project budget of €1.8M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call ERC-2014-CoG.
- Who coordinates the project?
- The project is coordinated by HUN-REN SZEGEDI BIOLOGIAI KUTATOKOZPONT (HU).
- What is the project timeline?
- The project runs from 2015-10-01 to 2022-03-31 — approximately 6.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 648364.